Top 7 Veterinary Prescription Anti-Inflammatory and Immunomodulatory Medications for Dogs in Canada (2025) - Evidence-Based Guide to Choosing the Right Option for Short and Long-Term Care

Novo-Prednisolone provides the active glucocorticoid prednisolone and is preferred in dogs where reliable systemic exposure is needed or where hepatic conversion of prednisone may be compromised. Technically it is advantageous over prednisone generics because it avoids metabolic activation variability, and while typically priced above basic generics like Apo-Prednisone, it can reduce therapeutic uncertainty and dose adjustments. Compared with potent agents such as dexamethasone and fixed-combination products (Temaril-P, Vanectyl-P), Novo-Prednisolone offers a middle ground of predictable pharmacokinetics and flexible dosing without adding the cost or side effects profile of higher-potency steroids or specialty combinations.

Genesis Topical Spray combines gentamicin and betamethasone, making it best-in-class for canine cases where concurrent bacterial infection and inflammation are present because it treats both components in a single, prescription formulation. Compared with Cortavance's steroid-only product, Genesis can shorten overall therapy and reduce the immediate need for separate systemic antibiotics, though it typically carries higher per-unit cost and requires careful use to limit antibiotic selection pressure and stewardship concerns.

Previcox (firocoxib) is a highly COX-2 selective NSAID commonly used for once-daily management of canine osteoarthritis, known for its predictable dosing and favorable long-term safety profile. As a market leader for COX-2–specific therapy, Previcox competes by offering reliable efficacy combined with strong value where generics are available, often undercutting the cost of some branded short-term or perioperative options while maintaining a focused COX-2 benefit.

Librela is a best‑in‑class monoclonal antibody for canine osteoarthritis pain, uniquely targeting NGF to reduce chronic pain rather than itch, which differentiates it technically and commercially from dermatology‑focused products here. Although typically positioned at a premium price relative to itch therapies, Librela opens a large, complementary market in pain management and often justifies higher reimbursement and client willingness to pay because it directly improves mobility and quality of life.

Apoquel (oclacitinib) is a JAK inhibitor that provides rapid control of pruritus and inflammatory signs in allergic dogs, earning its market-leader role for fast symptomatic relief rather than as broad cytotoxic immunosuppression. Financially it can be cost-effective for short- to medium-term symptom control compared with long-term systemic agents like cyclosporine or mycophenolate, and its distinct mechanism makes it a commonly used adjunct or alternative depending on therapeutic goals.

Cyclosporine 2% ophthalmic ointment is a specialized topical immunomodulator formulated for ocular surface conditions in dogs, designed to maximize corneal and conjunctival retention while minimizing systemic absorption. Compared with dermal topical agents, it is technically optimized for the eye and therefore occupies a niche, often premium-priced position in veterinary practice; it is not a direct substitute for broader-cutaneous topical therapies but complements the treatment portfolio for ocular immunologic disease.

Adequan Canine (polysulfated glycosaminoglycan) is a long-established injectable disease-modifying agent that supports cartilage matrix production and joint health, earning its place as a market staple because of decades of clinical use and a broad veterinary familiarity. Compared with newer biologics on this list, Adequan is typically more cost-effective per treatment course and is often chosen as a first-line prescription option for owners seeking a time-tested, clinic-administered therapy rather than higher-cost monthly monoclonal antibodies.